- Home
- NYC vs MIRA Comparison
NYC vs MIRA Comparison
Compare NYC & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- MIRA
- Stock Information
- Founded
- NYC 2013
- MIRA 2020
- Country
- NYC United States
- MIRA United States
- Employees
- NYC N/A
- MIRA N/A
- Industry
- NYC Real Estate
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- MIRA Health Care
- Exchange
- NYC Nasdaq
- MIRA Nasdaq
- Market Cap
- NYC 25.4M
- MIRA 25.2M
- IPO Year
- NYC N/A
- MIRA 2023
- Fundamental
- Price
- NYC $9.85
- MIRA $1.53
- Analyst Decision
- NYC
- MIRA
- Analyst Count
- NYC 0
- MIRA 0
- Target Price
- NYC N/A
- MIRA N/A
- AVG Volume (30 Days)
- NYC 3.2K
- MIRA 8.5M
- Earning Date
- NYC 11-11-2025
- MIRA 11-11-2025
- Dividend Yield
- NYC N/A
- MIRA N/A
- EPS Growth
- NYC N/A
- MIRA N/A
- EPS
- NYC N/A
- MIRA N/A
- Revenue
- NYC $54,865,000.00
- MIRA N/A
- Revenue This Year
- NYC $8.40
- MIRA N/A
- Revenue Next Year
- NYC $1.62
- MIRA N/A
- P/E Ratio
- NYC N/A
- MIRA N/A
- Revenue Growth
- NYC N/A
- MIRA N/A
- 52 Week Low
- NYC $7.89
- MIRA $0.73
- 52 Week High
- NYC $16.30
- MIRA $2.56
- Technical
- Relative Strength Index (RSI)
- NYC 45.54
- MIRA 56.69
- Support Level
- NYC $9.18
- MIRA $1.35
- Resistance Level
- NYC $9.97
- MIRA $2.45
- Average True Range (ATR)
- NYC 0.55
- MIRA 0.14
- MACD
- NYC 0.07
- MIRA 0.04
- Stochastic Oscillator
- NYC 54.92
- MIRA 23.35
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.